More than 1 in 4 people worldwide die from arterial thromboembolic events (ischemic heart disease or stroke). Anthos Therapeutics is highly committed to addressing this and other areas …

Anthos Therapeutics is a transformative, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic options for the treatment of cardiovascular metabolic diseases, founded by Blackstone Life Sciences (BXLS). Our initial focus is on the advancement of a novel anticoagulant therapy to address critical unmet needs in ...

Feb 11, 2025 · Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety

Aug 15, 2024 · CAMBRIDGE, Mass., Sept. 8, 2022 – Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of abelacimab for the prevention of stroke and ...

Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

CAMBRIDGE, Mass., Jan. 22, 2025–Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiovascular metabolic diseases, founded by Blackstone Life Sciences, announced today the publication of the results of the landmark AZALEA-TIMI 71 study in the January 23 ...

Aug 15, 2024 · CAMBRIDGE, Mass., May 5, 2022 – Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced that the first patient had been enrolled in a phase 3 clinical trial investigating a Factor XI agent. The ASTER study is one of two complementary, international ...

Anthos Therapeutics 99 High Street Boston, MA 02110 +1 617.430.6940. info@anthostherapeutics.com ...

Aug 15, 2024 · CAMBRIDGE, Mass., August 25, 2022 — Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced the initiation of recruitment for its second Phase 3 clinical trial investigating abelacimab, its novel dual-acting fully human monoclonal antibody targeting ...

Aug 15, 2024 · Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for high-risk cardiovascular patients.